In yesterday’s Wall Street session, INmune Bio Inc (NASDAQ:INMB) shares traded at $7.70, down -7.00% from the previous session.
INMB stock price is now -23.84% away from the 50-day moving average and -22.35% away from the 200-day moving average. The market capitalization of the company currently stands at $152.31M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $16, Robert W. Baird recently initiated with Outperform rating for INmune Bio Inc (NASDAQ: INMB). On May 24, 2022, B. Riley Securities Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $14 to quote $7, while ‘Maxim Group’ rates the stock as ‘Buy’
In other news, Juda Scott, Director bought 7,000 shares of the company’s stock on Nov 10 ’23. The stock was bought for $48,650 at an average price of $6.95. Upon completion of the transaction, the Director now directly owns 37,000 shares in the company, valued at $0.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 12 ’23, Director Schroeder Timothy j sold 10,000 shares of the business’s stock. A total of $110,085 was realized by selling the stock at an average price of $11.01. This leaves the insider owning 82,187 shares of the company worth $0.63 million. A total of 32.20% of the company’s stock is owned by insiders.
During the past 12 months, INmune Bio Inc has had a low of $6.50 and a high of $14.74. As of last week, the company has a debt-to-equity ratio of 0.27, a current ratio of 1.71, and a quick ratio of 1.71. The fifty day moving average price for INMB is $10.0576 and a two-hundred day moving average price translates $9.91395 for the stock.
The latest earnings results from INmune Bio Inc (NASDAQ: INMB) was released for 2024-03-31. The net profit margin was -26333.59% and return on equity was -81.82% for INMB. The company reported revenue of $14000.0 for the quarter, compared to $38000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -63.16 percent.
INmune Bio Inc(INMB) Company Profile
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
